Ajay Bansal Net Worth

The estimated Net Worth of Ajay Bansal is at least $758 Tausend dollars as of 18 January 2017. Mr. Bansal owns over 62,597 units of Urovant Sciences Ltd stock worth over $757,824 and over the last 21 years he sold UROV stock worth over $0. In addition, he makes $0 as Chief Financial Officer, Senior Vice President - Business Development und Principal Financial Officer at Urovant Sciences Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Bansal UROV stock SEC Form 4 insiders trading

Ajay has made over 1 trades of the Urovant Sciences Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 62,597 units of UROV stock worth $198,432 on 18 January 2017.

The largest trade he's ever made was buying 62,597 units of Urovant Sciences Ltd stock on 18 January 2017 worth over $198,432. On average, Ajay trades about 2,087 units every 0 days since 2004. As of 18 January 2017 he still owns at least 70,104 units of Urovant Sciences Ltd stock.

You can see the complete history of Mr. Bansal stock trades at the bottom of the page.

Ajay Bansal biography

Ajay Bansal is Chief Financial Officer, Senior Vice President - Business Development, Principal Financial Officer of the Company. Mr. Bansal brings over 16 years of finance, business development, accounting and mergers and acquisitions experience as a Chief Financial Officer for several leading and innovative biotechnology companies such as Onconova Therapeutics, Inc., Complete Genomics, Lexicon Pharmaceuticals, Inc., Tercica, Inc., Nektar Therapeutics and most recently with ViewRay, Inc. From June 2016 to September 2019, Mr. Bansal served as Chief Financial Officer of ViewRay, Inc., a designer and manufacturer of the MRIdian® radiation therapy system. From March 2013 to February 2016, he served as Chief Financial Officer of Onconova Therapeutics, a phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Prior to his leadership roles as Chief Financial Officer, Mr. Bansal spent over 15 years as a management consultant with firms such as McKinsey & Company and ZS Associates, Inc., and in various management positions at Novartis, a pharmaceutical company, and at Mehta Partners, a financial advisory firm. Mr. Bansal received a B.S. in Mechanical Engineering from the Indian Institute of Technology (Delhi) and an M.S. in Operations Research and an M.B.A. from Northwestern University.

How old is Ajay Bansal?

Ajay Bansal is 58, he's been the Chief Financial Officer, Senior Vice President - Business Development und Principal Financial Officer of Urovant Sciences Ltd since 2019. There are 3 older and 4 younger executives at Urovant Sciences Ltd. The oldest executive at Urovant Sciences Ltd is Myrtle Potter, 61, who is the Chairman of the Board.

What's Ajay Bansal's mailing address?

Ajay's mailing address filed with the SEC is C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVE., SUITE 100, IRVINE, CA, 92617.

Insiders trading at Urovant Sciences Ltd

Over the last 6 years, insiders at Urovant Sciences Ltd have traded over $0 worth of Urovant Sciences Ltd stock and bought 22,782,569 units worth $411,146,115 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... und Andrew Lo. On average, Urovant Sciences Ltd executives and independent directors trade stock every 6 days with the average trade being worth of $6,293,420. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 19 February 2020, trading 103,250 units of UROV stock currently worth $1,350,510.

What does Urovant Sciences Ltd do?

Complete history of Mr. Bansal stock trades at Lexicon Pharmaceuticals Inc, Nektar Therapeutics, Onconova Therapeutics Inc, ViewRay und Urovant Sciences Ltd

Urovant Sciences Ltd executives and stock owners

Urovant Sciences Ltd executives and other stock owners filed with the SEC include:

• Cornelia Haag-Molkenteller,
  Chief Medical Officer of USI
• Bryan Smith,
  General Counsel - USI
• Michael McFadden,
  Chief Commercial Officer
• Christine Ocampo,
  Senior Vice President, Chief Accounting Officer, Principal Accounting Officer
• Kenton Stewart,
  Senior Vice President of Market Access
• Walt Johnston,
  Senior Vice President of Commercial
• James Hindman,
  Director
• Shigeyuki Nishinaka,
  Director
• Ajay Bansal,
  Chief Financial Officer, Senior Vice President - Business Development, Principal Financial Officer
• Myrtle Potter,
  Chairman of the Board
• James Robinson,
  Principal Executive Officer, Director
• Pierre Legault,
  Independent Director
• Sef Kurstjens,
  Independent Director
• Holdings Ltd.Dexcel Pharma ...,
  
• Associates Gp Llcqvt Fund V...,
  
• Patrick Machado,
  
• Frank Torti,
  Director
• Global Investors Lp Viking ...,
  
• Investments (Uk) Ltd Soft B...,
  
• Nori Ebersole,
  SVP&CHRO-Urovant Sciences,Inc.
• Global Performance Llc Viki...,
  
• Sciences Ltd. Roivant,
  10% owner
• Andrew Lo,
  
• Global Performance Llc Viki...,
  
• Associates Gp Llcqvt Financ...,
  
• Chemical Co., Ltd.Sumitomo ...,
  
• Keith Katkin,
  PEO;CEO/Urovant Sciences, Inc.